MRKR (Marker Therapeutics) Short Percentage of Float


MRKR Marker Therapeutics Inc MRKR
32 GF Score
Price $1.49
! 1 Warning Sign
View Full Analysis

What is Marker Therapeutics Short Percentage of Float?

Short Percentage of Float is the percentage of shares shorted compared to the float.

Due to the license agreement change with our data vendor, Short Interest related data on GuruFocus will no longer be updated. Existing data will remain as-is, while new data will not be available, except for certain Australian and Canadian stocks.

MRKR vs PLUR, VYNE, LGVN: Short Percentage of Float Comparison

For the Biotechnology subindustry, Marker Therapeutics's Short Percentage of Float, along with its competitors' market caps and Short Percentage of Float data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Marker Therapeutics Short Percentage of Float vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Marker Therapeutics's Short Percentage of Float distribution charts can be found below:

* The bar in red indicates where Marker Therapeutics's Short Percentage of Float falls into.


MRKR
32GF Score
Marker Therapeutics Inc MRKR
Short Percentage of Float is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Marker Therapeutics Business Description

Other Exchanges GX1:Germany
Address 2450 Holcombe Boulevard, TMC Partners Office 1.311, Houston, TX, USA, 77021
Marker Therapeutics Inc is a clinical-stage immuno-oncology company specializing in the development and commercialization of novel T cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The company develops product candidates from MAR-T cell technology, which is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor-associated antigens, or TAAs, which are tumor targets, and then kill tumor cells. These T cells are designed to recognize multiple tumor targets to produce broad spectrum anti-tumor activity. Its pipeline products include: Autologous MAR-T cell product for the treatment of lymphoma and pancreatic cancer (MT-601), and Off-the-Shelf (OTS) products (MT-401-OTS).
32GF Score

Get the complete analysis for MRKR

Short Percentage of Float is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.49
Price